Recombinant gp350 vaccine for infectious mononucleosis: a phase 2, randomized, double-blind, placebo-controlled trial to evaluate the safety, immunogenicity, and efficacy of an Epstein-Barr virus vaccine in healthy young adults

The Journal of Infectious Diseases
Etienne M SokalMartine Denis

Abstract

To date, there is no commercially available vaccine to prevent infectious mononucleosis, a disease frequently induced by Epstein-Barr virus (EBV) infection in adolescents or adults devoid of preexisting immunity to the virus. A total of 181 EBV-seronegative, healthy, young adult volunteers were randomized in a double-blind fashion to receive either placebo or a recombinant EBV subunit glycoprotein 350 (gp350)/aluminum hydroxide and 3-O-desacyl-4'-monophosphoryl lipid A (AS04) candidate vaccine in a 3-dose regimen. The vaccine had demonstrable efficacy (mean efficacy rate, 78.0% [95% confidence interval {CI}, 1.0%-96.0%]) in preventing the development of infectious mononucleosis induced by EBV infection, but it had no efficacy in preventing asymptomatic EBV infection. One month after receipt of the final dose of gp350 vaccine, 98.7% of subjects showed seroconversion to anti-gp350 antibodies (95% CI, 85.5%-97.9%), and they remained anti-gp350 antibody positive for >18 months. Furthermore, there were no concerns regarding the safety or reactogenicity of the gp350/AS04 vaccine. These data support the clinical feasibility of using an EBV vaccine to prevent infectious mononucleosis. ClinicalTrials.gov identifier: NCT00430534.

References

Aug 15, 1998·Journal of Virological Methods·A D Wilson, A J Morgan
Jun 7, 2002·Journal of Pediatric Gastroenterology and Nutrition·Françoise Smets, Etienne M Sokal
Oct 3, 2003·The New England Journal of Medicine·Henrik HjalgrimMads Melbye
Sep 30, 2005·The New England Journal of Medicine·Karen M Kim, Richard I Kopelman
Feb 28, 2006·Annals of Neurology·Evan L ThackerAlberto Ascherio
Jun 29, 2006·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Dorothy H CrawfordAnthony J Swerdlow

❮ Previous
Next ❯

Citations

Jan 27, 2011·Cancer Immunology, Immunotherapy : CII·Federica CavalloPier-Luigi Lollini
Apr 7, 2010·Journal of Neuroimmune Pharmacology : the Official Journal of the Society on NeuroImmune Pharmacology·Alberto Ascherio, Kassandra L Munger
Apr 4, 2013·Current Treatment Options in Oncology·Jennifer A Kanakry, Richard F Ambinder
Aug 12, 2009·Current Neurology and Neuroscience Reports·Bridget A Bagert
Aug 19, 2010·Immunologic Research·Ting-Ting WuRen Sun
Feb 9, 2011·Immunology and Cell Biology·Daniëlle HorstEmmanuel J H J Wiertz
May 28, 2010·The New England Journal of Medicine·Katherine Luzuriaga, John L Sullivan
Jan 15, 2008·The Journal of Infectious Diseases·Henry H Balfour
Mar 16, 2013·The Journal of Infectious Diseases·Henry H Balfour, Priya Verghese
Oct 13, 2009·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·Foteini KoukourgianniPierre Cochat
Jun 21, 2012·JAAPA : Official Journal of the American Academy of Physician Assistants·Stacey Singer-Leshinsky
Nov 4, 2011·Science Translational Medicine·Jeffrey I CohenGary J Nabel
Jan 15, 2011·Clinical Microbiology Reviews·Oludare A OdumadeHenry H Balfour
Dec 14, 2012·Journal of Virology·Sophia PavlovaHenri-Jacques Delecluse
Oct 14, 2011·Journal of Virology·Romana RuissReinhard Zeidler
Apr 28, 2010·Annual Review of Microbiology·John T Schiller, Douglas R Lowy
Nov 16, 2010·The Neuroscientist : a Review Journal Bringing Neurobiology, Neurology and Psychiatry·Michael P Pender
Feb 1, 2012·Multiple Sclerosis : Clinical and Laboratory Research·Kelly Claire SimonAlberto Ascherio
Nov 22, 2011·PLoS Pathogens·Miguel GasparPhilip G Stevenson
Nov 25, 2011·PLoS Pathogens·Bénédicte MachielsLaurent Gillet
Oct 3, 2012·PLoS Pathogens·Bruno FredericoPhilip G Stevenson
Dec 4, 2012·International Journal of Molecular Sciences·Ai-Di GuChao-Nan Qian
Mar 22, 2014·Science·Paul M Lieberman
Jun 6, 2014·Nature Medicine·David Holmes
Jan 1, 2014·Vaccines·Deana N Toussi, Paola Massari
Apr 14, 2012·Advances in Virology·Sajal K GhoshDouglas V Faller
Apr 4, 2014·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Henry H Balfour
May 14, 2014·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Lawrence M CondonHenry H Balfour
Dec 17, 2014·Clinical & Translational Immunology·Michael P Pender, Scott R Burrows
Sep 8, 2015·Vaccines·Giovanni CaponeDarja Kanduc
Mar 13, 2016·Seminars in Oncology·Priscila H GoncalvesThomas S Uldrick
May 15, 2013·Vaccine·Xinle CuiClifford M Snapper
Apr 9, 2013·Current Opinion in Virology·Fred Wang
Sep 18, 2015·Cancer Medicine·Vidya VedhamSomdat Mahabir
Jul 17, 2012·Current Opinion in Virology·Ting-Ting WuRen Sun
Nov 29, 2011·Néphrologie & thérapeutique·Gwenaelle Roussey-Kesler, Stéphane Decramer

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.